New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
about
Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Molecular testing in lung cancer in the era of precision medicineManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerUnravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approachesSignaling cross-talk in the resistance to HER family receptor targeted therapyMolecular pathology of non-small cell lung cancer: a practical guide.Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patientsThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyHedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinomaReduced NF1 expression confers resistance to EGFR inhibition in lung cancerThe salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyCoexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.The new concepts on overcoming drug resistance in lung cancer.p120-catenin modulates airway epithelial cell migration induced by cigarette smokeEGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaA phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Recent advances in immunotherapy for non-small-cell lung cancer.Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutationMechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation.Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast CancerDiagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationIlluminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Screening for germline EGFR T790M mutations through lung cancer genotyping.EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.Genetic and biochemical alterations in non-small cell lung cancer.The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib.Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.EGFR tyrosine kinase inhibition induces autophagy in cancer cells.Erlotinib resistance in lung cancer: current progress and future perspectives.
P2860
Q26739760-24574080-B6CF-401A-A8DA-4CA7147D90A8Q26741814-E96BA2D5-5C1D-4419-8B02-C6611ED0DF5CQ26824599-9B594F00-7743-4FBB-AE50-39CB430054B1Q26865779-C54DF703-F1DB-41FB-B836-6B8220853A21Q27008332-50AFDB20-D824-466D-8679-CCB9C4C9CA15Q27027778-DAE6F93B-3605-42FC-85B7-5AFA3CC7DA75Q27690919-85DDCD94-4476-44C3-AA4F-1F41DB26C2EEQ27852993-03FD7CA4-0ED9-4637-937D-8FD200D00C7EQ28073335-C211A71B-94E8-4E7B-96CC-726A22F5CCFBQ28595500-EC449972-6BF0-42E5-BEBE-E2972C536E67Q33572728-6E4587BC-E0D1-454A-B551-074815DD9161Q33655128-81373A69-4193-4E49-9E71-1954486BDD11Q33682941-6DAD62D4-7ABF-409F-8BBA-3F9DC6373D04Q33706859-E63C6EDC-EA9B-41F3-974B-E66C1089B985Q33754114-9BAA45A9-C290-4CE6-8CFB-79DE92E711CFQ33791598-9CFBAAD9-94AB-4E1D-B8AD-80CEFE919F33Q34108365-50CAA820-DFB8-4597-8D67-954DAC5F5056Q34180815-1D97784F-4BFE-4A46-A5FC-0B0E5BB22EC3Q34260686-65CA0DAB-7BF0-47CB-B474-5190E290916CQ34290801-A75E0E69-EF31-4391-91F4-5A8B8A2EE489Q34293223-A7FA77DD-1E0C-40FE-8FEF-F76BB3EA3F70Q34359274-81D88454-B374-4F09-8A33-9E55277C14A2Q34433903-7357E350-F7E5-4550-990C-DBDEE73D1B8BQ34465240-A14B6A5F-B3C9-4F2E-AF81-6F5619409A39Q35040888-7788DEDF-8E10-49A3-8092-0BA03BD7CA46Q35076221-E968212A-A0D9-4ABD-A545-B1E14B6F11E4Q35152542-C22019EB-83EE-44CF-A5F6-DFC2E3B19C6DQ35180028-0409ED56-D95F-4AF5-B893-7F75CABAE858Q35533514-B254BA9D-9898-429B-BF0F-CD0740EC72DDQ35875227-6AB2F692-A894-45A7-81F0-14E605103077Q35944914-595056B7-862C-4FE1-8940-B851695B86BCQ35967349-B0DC4F0C-33D4-4DF9-9D5A-4B78D4301EF6Q36102842-9F6CE7C9-F99E-4091-9557-DAA8768BF650Q36184584-8A97F449-141E-44EB-BE23-CECCDD20217FQ36205477-E606FBA3-BD93-4259-8296-4C2642F6EFDAQ36228558-1CCC9A3A-B2D2-40F7-A9B5-91DD69AFBCEFQ36382921-7B3C43ED-D5EA-4D86-9868-4BF430D653C6Q36511007-CC12D410-357E-4722-BEC6-5BE52D124439Q36524211-FC0BD895-A088-4226-BB01-BB6277B597F3Q36605522-B393B38C-0F68-4EAB-A631-71DE451D2FB6
P2860
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@ast
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@en
type
label
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@ast
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@en
prefLabel
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@ast
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@en
P2093
P2860
P50
P1476
New strategies in overcoming a ...... ase inhibitors in lung cancer.
@en
P2093
Geoffrey R Oxnard
Maria E Arcila
Vincent A Miller
P2860
P304
P356
10.1158/1078-0432.CCR-10-2571
P407
P577
2011-07-20T00:00:00Z